Abstract
The genetic alterations associated with breast carcinogenesis are well known. On the contrary epigenetic alterations in hereditary breast cancer are a new field. Two epigenetic mechanisms have emerged as the most critical players in transcriptional regulation in breast cancer: the methylation of DNA and microRNA interference.
In this review we will focus on recent findings on gene silencing caused by DNA methylation and microRNA to explore the potential role of these epigenetic changes in the understanding of hereditary breast cancer. Moreover we will describe the same alterations in basal-like breast cancer and in triple-negative breast cancer, since their phenotypes have similarities with BRCA1-mutated tumors. To underline the possibility that some epigenetic alterations could also be used as potential epigenetic biomarkers of drug sensitivity or resistance, we will discuss the more common therapies in hereditary breast cancer that could also be applied to breast cancer with basal-like or triple negative phenotypes.
Keywords: Basal-like breast cancer, BRCA1, hereditary breast cancer, methylation, miRNA, triple-negative breast cancer.
Current Molecular Medicine
Title:DNA Methylation and miRNAs Regulation in Hereditary Breast Cancer: Epigenetic Changes, Players in Transcriptional and Post- Transcriptional Regulation in Hereditary Breast Cancer
Volume: 14 Issue: 1
Author(s): R. Pinto, S. De Summa, B. Pilato and S. Tommasi
Affiliation:
Keywords: Basal-like breast cancer, BRCA1, hereditary breast cancer, methylation, miRNA, triple-negative breast cancer.
Abstract: The genetic alterations associated with breast carcinogenesis are well known. On the contrary epigenetic alterations in hereditary breast cancer are a new field. Two epigenetic mechanisms have emerged as the most critical players in transcriptional regulation in breast cancer: the methylation of DNA and microRNA interference.
In this review we will focus on recent findings on gene silencing caused by DNA methylation and microRNA to explore the potential role of these epigenetic changes in the understanding of hereditary breast cancer. Moreover we will describe the same alterations in basal-like breast cancer and in triple-negative breast cancer, since their phenotypes have similarities with BRCA1-mutated tumors. To underline the possibility that some epigenetic alterations could also be used as potential epigenetic biomarkers of drug sensitivity or resistance, we will discuss the more common therapies in hereditary breast cancer that could also be applied to breast cancer with basal-like or triple negative phenotypes.
Export Options
About this article
Cite this article as:
Pinto R., Summa De S., Pilato B. and Tommasi S., DNA Methylation and miRNAs Regulation in Hereditary Breast Cancer: Epigenetic Changes, Players in Transcriptional and Post- Transcriptional Regulation in Hereditary Breast Cancer, Current Molecular Medicine 2014; 14 (1) . https://dx.doi.org/10.2174/1566524013666131203101405
DOI https://dx.doi.org/10.2174/1566524013666131203101405 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Cell Growth by Estrogen Signaling and Potential Targets in Thyroid Cancer
Current Cancer Drug Targets Modern Alchemy with Metal Complexes Inside Cyclodextrins, The Molecular Cauldrons
Current Organic Chemistry Brain Tumour Stem Cells: Implications for Cancer Therapy and Regenerative Medicine
Current Stem Cell Research & Therapy In Vitro Inhibition Effect and Molecular Docking Study of Curcumin, Resveratrol, and Quercetin on Human Erythrocyte Glutathione Transferase
Current Enzyme Inhibition Novel Carbamοyloxy Analogues of Tamoxifen: Synthesis, Molecular Docking and Bioactivity Evaluation
Letters in Drug Design & Discovery The Medicinal Chemistry of Theragnostics, Multimodality Imaging and Applications of Nanotechnology in Cancer
Current Topics in Medicinal Chemistry Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry Cadmium and Its Epigenetic Effects
Current Medicinal Chemistry Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Targeting Allosteric Control Mechanisms in Heat Shock Protein 70 (Hsp70)
Current Topics in Medicinal Chemistry Editorial
Current Medical Imaging Treatment Approaches in Elderly Patients with Head and Neck Cancer
Anti-Cancer Agents in Medicinal Chemistry Emerging Immunotargets in Bladder Cancer
Current Drug Targets Multidrug Resistance Through the Spectacle of P-Glycoprotein
Current Cancer Drug Targets Meet Our Editorial Board Member:
Current Drug Targets Radiological Assessment of Giant Cell Tumour of Bone in the Sacrum: From Diagnosis to Treatment Response Evaluation
Current Medical Imaging Global Gastrointestinal Safety Profile of Etoricoxib and Lumiracoxib
Current Pharmaceutical Design Quinoxalinone as a Privileged Platform in Drug Development
Mini-Reviews in Medicinal Chemistry The Type II Transmembrane Serine Protease, Matriptase-2: Possible Links to Cancer?
Anti-Cancer Agents in Medicinal Chemistry Bone Morphogenetic Proteins and its Receptors; Therapeutic Targets in Cancer Progression and Bone Metastasis?
Current Pharmaceutical Design